AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 15996811
Drug: Doxazosin gastrointestinal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin gastrointestinal therapeutic system (DOX GITS) 4 mg/d
Trial: 14507273
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (Ca) 1 g
Trial: 14507273
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (Ca) 2 g
Trial: 14507273
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (Ca) 4 g
Trial: 14507273
Drug: Oral calcium
RxNorm normalized name: Coral Calcium
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral calcium (Ca)
Trial: 8644427
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy including 5-fluorouracil and leucovorin
Trial: 8644427
Drug: Fluorouracil in
RxNorm normalized name: fluorouracil Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluorouracil in combination with levamisole or leucovorin
Trial: 1998792
Drug: Stopping the
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stopping the combined oral contraceptive pill
Trial: 6147193
Drug: SCH 399
RxNorm normalized name: SCH 58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCH 399 syrup (combination of azatadine maleate, pseudoephedrine sulfate, and dextromethorphan hydrobromide)
Trial: 6147193
Drug: Expectorant containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectorant containing diphenhydramine hydrochloride
Trial: 14579028
Drug: Nonoperative therapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonoperative therapy, including modification of sports and recreational activities
Trial: 10862585
Drug: Intravenous flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous flecainide (n = 39)
Trial: 10862585
Drug: Oral flecainide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral flecainide (n = 40)
Trial: 1420057
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of Diamox Sustets (acetazolamide) 1 hour preoperatively
Trial: 1420057
Drug: Combined treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined treatment of acetazolamide and acetylcholine
Trial: 31063198
Drug: Infant oral
RxNorm normalized name: Dolono Infant Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant oral microbiome
Trial: 30092157
Drug: 1000 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 IU/day vitamin D (cholecalciferol, Calcirol® sachet) administered as a stat dose of 90,000 IU every three months.
Trial: 30092157
Drug: 400 IU/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 IU/day vitamin D (cholecalciferol) administered as a stat dose of 36,000 IU every three months.
Trial: 24770498
Drug: Topical potassium
RxNorm normalized name: Topicale
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical potassium hydroxide therapy
Trial: 20458465
Drug: Transcutaneous electrical
RxNorm normalized name: Transcutaneous Electrical Nerve Stimulators (TENS Units) MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcutaneous electrical tibial nerve stimulation (TTNS) in addition to standard therapy (bladder retraining and pelvic floor muscle exercises)
Trial: 20458465
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (bladder retraining and pelvic floor muscle exercises)
Trial: 12483094
Drug: Latanoprost 0.005%
RxNorm normalized name: LATANOPROST 0.005% SOLN,OPH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Latanoprost 0.005% once daily for 8 weeks
Trial: 12483094
Drug: Isopropyl unoprostone
RxNorm normalized name: isopropyl unoprostone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isopropyl unoprostone 0.12% twice daily for 8 weeks
Trial: 10682558
Drug: Epimedium compound
RxNorm normalized name: Epimedium grandiflorum top extract
DrugBank: Epimedium grandiflorum top (DB14301)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epimedium compound granules
Trial: 589554
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy including vincristine at 3-week intervals
Trial: 589554
Drug: Other therapies
RxNorm normalized name: Theraplex Eczema Therapy
DrugBank: Colloidal oatmeal (DB11286)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapies or no therapy
Trial: 26179284
Drug: Probiotics (a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotics (a widely available food supplement with a low risk safety profile)
Trial: 21311504
Drug: 60,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60,000 IU monthly oral vitamin D(3) for 16 weeks
Trial: 15652899
Drug: Isolated isoflavones
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated isoflavones (114 mg daily for 3 months)
Trial: 9689393
Drug: Pancuronium (0.09
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancuronium (0.09 mg kg‐1, n = 10)
Trial: 9689393
Drug: Pipecuronium (0.08
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pipecuronium (0.08 mg kg‐1, n = 10)
Trial: 9689393
Drug: Atracurium (0.6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atracurium (0.6 mg kg‐1, n = 10)
Trial: 9689393
Drug: Vecuronium (0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vecuronium (0.1 mg kg‐1, n = 10)
Trial: 7857439
Drug: Intracervical prostaglandin
RxNorm normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracervical prostaglandin E2 (PGE2) 0.5 mg
Trial: 7857439
Drug: Intravenous oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous oxytocin (if labor not established)
Trial: 2678652
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg tolfenamic acid
Trial: 30779718
Drug: Daily fluid
RxNorm normalized name: ENSULIZOLE 4 g in 100 mL / OCTINOXATE 5 g in 100 mL / OCTOCRYLENE 10 g in 100 mL / TITANIUM DIOXIDE 5 g in 100 mL / OCTISALATE 5 g in 100 mL TOPICAL CREAM [EXEL CLARIFYING LINE DAILY FLUID SUN SHIELD WHITE COLOR BROAD SPECTRUM SPF 60 PLUS]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily fluid balance, tidal volume, plateau pressure, positive end-expiratory pressure
Trial: 23996292
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg ketoprofen in 4.4 g transfersome gel (IDEA-033)
Trial: 23996292
Drug: 4.4 g
RxNorm normalized name: ALUMINUM CHLOROHYDRATE 4.4 g in 1 mg BUCCAL EMULSION [Antiperspirant]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.4 g ketoprofen-free vehicle (TDT 064)
Trial: 21756276
Drug: Colour Doppler
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colour Doppler ultrasonography with SonoVue™ contrast agent
Trial: 16995327
Drug: Valdecoxib (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valdecoxib (20 mg, o.d.)
Trial: 16995327
Drug: Rofecoxib (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rofecoxib (25 mg, o.d.)
Trial: 12734781
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine (overweight subgroup)
Trial: 12734781
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (overweight subgroup)
Trial: 9876706
Drug: Intermittent intramuscular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent intramuscular injection of morphine
Trial: 31004689
Drug: Balance training
RxNorm normalized name: Rebalance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Balance training (exercised twice a week for 12 weeks)
Trial: 25586727
Drug: Fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinogen concentrate (2 g or equivalent)
Trial: 19549431
Drug: Ciclesonide 80
RxNorm normalized name: CICLESONIDE 80MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 80 microg twice daily (CIC80 b.i.d.)
Trial: 19549431
Drug: Ciclesonide 160
RxNorm normalized name: CICLESONIDE 160MCG 60D ORAL INHL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciclesonide 160 microg once daily (CIC160 q.d.)
Trial: 19549431
Drug: Ciclesonide treatments
RxNorm normalized name: Ciclesonide
DrugBank: Ciclesonide (DB01410)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciclesonide treatments (CIC80 b.i.d. and CIC160 q.d.)
Trial: 16428009
Drug: Standard vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard vaccine information sheets
Trial: 11348454
Drug: Long-term (192
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Long-term (192 wk) all‐trans retinoic acid treatment (n = 5)
Trial: 9237602
Drug: Beta Blockers
RxNorm normalized name: BETA BLOCKERS/RELATED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta Blockers (BB)
Trial: 26911315
Drug: Polyunsaturated fatty
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polyunsaturated fatty acids (PUFA) lotion 12%
Trial: 22305830
Drug: RLX030 (recombinant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RLX030 (recombinant form of human relaxin 2) 30 μg/kg per day IV infusion for 48 hours
Trial: 20132129
Drug: Octreotide infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Octreotide infusion (30 ng (kg min)(‐1))
Trial: 20132129
Drug: Control (sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (sodium chloride infusion)
Trial: 12514144
Drug: Desmopressin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.3 micro g x kg(‐1) infused intravenously over 20 min)
Trial: 1510006
Drug: 0.05 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.05 mg/kg diltiazem
Trial: 1510006
Drug: 0.15 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.15 mg/kg diltiazem
Trial: 1510006
Drug: 0.25 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 mg/kg diltiazem
Trial: 1510006
Drug: 0.45 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.45 mg/kg diltiazem
Trial: 1510006
Drug: Diltiazem (0.15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diltiazem (0.15 to 0.45 mg/kg)
Trial: 6090367
Drug: MDF (6141
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDF (6141 cGy, 69 fractions, 4 1/2 weeks, at 89 cGy every 4 hours 3 times daily)
Trial: 6090367
Drug: MDF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MDF plus MISO (1.25 gm/M2 three times weekly for the first 3 weeks)
Trial: 6090367
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose MDF (7120 cGy, 80 fractions, 5 1/2 weeks, at 89 cGy per fraction every 4 hours 3 times daily)
Trial: 27652585
Drug: Sham feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham feeding with gum chewing (two pieces of xylitol flavored gum for 15 minutes, three times a day after extubation until oral nutrition was tolerated)
Trial: 24964348
Drug: Setipiprant 1000
RxNorm normalized name: Setipiprant
DrugBank: Setipiprant (DB12562)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Setipiprant 1000 mg b.i.d. for 5 days
Trial: 21979440
Drug: 60 g
RxNorm normalized name: aspirin 60 Grains
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 g glucose dose after an overnight fast
Trial: 21979440
Drug: 25 g
RxNorm normalized name: AndroGel 1.25 g Packets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 g glucose dose after a 2-hour fast
Trial: 17311061
Drug: TPN with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPN with glutamine (0.3 g/kg/days)
Trial: 2643904
Drug: Sustained-release theophylline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained-release theophylline (THEO)
Trial: 2643904
Drug: Inhaled bitolterol
RxNorm normalized name: bitolterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled bitolterol (BITOL)
Trial: 1146718
Drug: Micronor (progestogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micronor (progestogen type oral contraceptive)
Trial: 1146718
Drug: Ortho‐Novum SQ
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ortho‐Novum SQ (sequential type oral contraceptive)
Trial: 1146718
Drug: Control cycle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control cycle (no oral contraceptives)
Trial: 23816814
Drug: levocetirizine hydrochloride
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levocetirizine hydrochloride 5 mg (Xyzal®) administered on day 8 after placebo for 7 days (treatment B)
Trial: 23816814
Drug: levocetirizine hydrochloride
DrugBank: Levocetirizine (DB06282)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: levocetirizine hydrochloride 5 mg (Xyzal®) administered for 8 days (treatment C)
Trial: 23816814
Drug: placebo administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo administered for 8 days (treatment A)
Trial: 19267954
Drug: Sham-fed meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham-fed meal 2 (oral-stimulation)
Trial: 17224218
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine in combination with varicella (MMR and V)
Trial: 15169694
Drug: Risperidone (1‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (1‐6 mg/day)
Trial: 9572210
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 2.5 mg + E1 sulfate 1.25 mg
Trial: 9572210
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 5 mg + E1 sulfate 1.25 mg
Trial: 9572210
Drug: Medroxyprogesterone acetate
RxNorm normalized name: Medroxyprogesterone Acetate
DrugBank: Medroxyprogesterone acetate (DB00603)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone acetate 10 mg + E1 sulfate 1.25 mg
Trial: 7999348
Drug: Behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral treatment of depression in dementia patients
Trial: 2741997
Drug: Sensorimotor integrative
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sensorimotor integrative treatment
Trial: 30101636
Drug: Conventional treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment, biologics, and no treatment
Trial: 22211956
Drug: Alfuzosin 10
RxNorm normalized name: Alfuzosin 10mg Oral tablet, extended release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alfuzosin 10 mg + Sildenafil 50 mg
Trial: 20304413
Drug: High protein,
RxNorm normalized name: Ensure High Protein, Banana, Instant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein, low carbohydrate diet (20 g/d)
Trial: 8758170
Drug: Thiopentone 5
RxNorm normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Thiopentone 5 mg.kg‐1 preceded by 40 mg of topical lignocaine spray
Trial: 8758170
Drug: Propofol 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propofol 2.5 mg.kg‐1 alone
Trial: 2206072
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 chip (3.0 mg)
Trial: 30816331
Drug: Weekly doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly doxorubicin
Trial: 26077176
Drug: Sapropterin (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sapropterin (5 mg/kg/day increased to 10 mg/kg on day 8)
Trial: 24717838
Drug: Brivaracetam single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam single dose (2.5-100 mg)
Trial: 24717838
Drug: Brivaracetam multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brivaracetam multiple dose (2.5-50 mg twice daily)
Trial: 22791079
Drug: Biotin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biotin (1 mg/day)
Trial: 17013636
Drug: Active tea
RxNorm normalized name: IODINE 100 g in 100 g TOPICAL CREAM [Active Teat Cream]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active tea treatment (n = 37)
Trial: 11940691
Drug: Nimesulide 100
RxNorm normalized name: nimesulide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100 mg by mouth twice daily
Trial: 7631673
Drug: Observation phase
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observation phase (no treatment)
Trial: 7631673
Drug: Treatment phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase (clindamycin 300 mg orally twice daily for 7 days)
Trial: 7631673
Drug: Treatment phase
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment phase (clindamycin for bacterial vaginosis and trichomoniasis)
Trial: 30517071
Drug: Intensive preventive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive preventive protocol (subgroups A1, B1, C1) including topical application of fluoride, brushing with 5000-ppm fluoride toothpaste, use of amorphous calcium phosphate-casein phosphopeptide, applications of sealants for occlusal lesions (ICDAS code 2), and minimal resin restorations for occlusal lesions (ICDAS code 3)
Trial: 30517071
Drug: Instructions in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructions in oral hygiene (subgroups A2, B2, C2)
Trial: 30517071
Drug: Instructions in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Instructions in oral hygiene (subgroup C2)
Trial: 25826741
Drug: Nitrate supplementation
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate supplementation (beetroot juice; 5 mm, 0.45 g nitrates per day for 3 days)
Trial: 25826741
Drug: Control (Ringer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (Ringer solution)
Trial: 8194141
Drug: Subcutaneous morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous morphine infusion
Trial: 2694339
Drug: Chloramphenicol (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloramphenicol (total daily dosage, 2 g) plus placebo
Trial: 2694339
Drug: Furazolidone (total
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furazolidone (total daily dosage, 800 mg) plus placebo
Trial: 846510
Drug: Hyaluronidase treatment
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase treatment (administered intravenously after the first electrocardiogram and every six hours for 48 hours)
Trial: 846510
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no hyaluronidase treatment)
Trial: 846510
Drug: Hyaluronidase treatment
RxNorm normalized name: Hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Hyaluronidase treatment
Trial: 11589259
Drug: Codeine 60
RxNorm normalized name: codeine 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Codeine 60 mg/acetaminophen 600 mg
Trial: 27348762
Drug: Candesartan (32
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Candesartan (32 mg/d)
Trial: 17647145
Drug: Insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Insulin detemir (0.15, 0.3, 0.6 U/kg)
Trial: 17647145
Drug: NPH insulin
RxNorm normalized name: NPH Insulin, Human 300 UNT per 3 ML Prefilled Syringe
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NPH insulin (0.15, 0.3, 0.6 IU/kg)
Trial: 10550081
Drug: Insulin four
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Insulin four times daily regimen
Trial: 10550081
Drug: Insulin twice
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Insulin twice daily regimen
Trial: 7607776
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of self-report, urinalysis, and hair analysis
Trial: 2254836
Drug: Clindamycin hydrochloride
RxNorm normalized name: Clindamycin Hydrochloride
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clindamycin hydrochloride as an adjunct to scaling
Trial: 26846356
Drug: Topical steroids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical steroids alone (Group A)
Trial: 26846356
Drug: Topical and
RxNorm normalized name: norgestimate and ethinylestradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical and oral steroids (Group B)
Trial: 7871235
Drug: Brief treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brief treatment sessions
Trial: 2970498
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of lithium and imipramine